Despite most adults in the U.S. being at risk for severe Covid, confusion persists over who qualifies for Paxlovid, leading to barriers in access.
Dr. Davey Smith notes that often providers lack experience prescribing Paxlovid, leading them to downplay its necessity, which can result in adverse outcomes for high-risk patients.
Paxlovid is a crucial treatment option for those with mild to moderate Covid symptoms who are at risk for severe illness, but it often goes underprescribed.
A study shows that only 15% of eligible patients actually use Paxlovid despite its established effectiveness in preventing severe disease, highlighting a significant gaps in treatment access.
[
Collection
]
[
|
...
]